CME: Systemic Sclerosis Interstitial Lung Disease (SSc-ILD): Optimizing Treatment Strategies
ACCREDITATION EXPIRED: August 20, 2020
Activity Description / Statement of Need:
In this online, self-learning activity:
Systemic sclerosis (SSc) is a rare connective tissue disease that affects 276 people per million in the U.S., of whom around 70% will experience interstitial lung disease (ILD). The disease is characterized by a progressive course of scarring to the blood vessels underlying the skin, connective tissue, joints, and organs. The pathology of SSc remains to be fully elucidated, but different immunologic and genetic pathways have been explored as potential precipitating factors for SSc. Based on what is known, SSc-ILD may be summarized into three steps: 1) continuous injury to endothelial cells, 2) activation of innate and adaptive immunity, 3) recruitment and activation of fibroblasts.
Target Audience:
The following HCPs: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with Ssc-ILD.
This program is supported by an educational grant from Boehringer Ingelheim.
Release Date: August 20, 2018 -- Expiration Date: August 20, 2020
Faculty: Terese Hammond, MD
Agenda
Cursory refresher and review on SSc-ILD epidemiology and diagnosis:
- Epidemiology and risk factors
- Pathophysiology
- Genetic abnormalities
- Immune dysfunction
- Overactivation of fibroblasts
- Bilateral inspiratory auscultation
- Dyspnea on exertion
- Nonproductive cough
- Diagnosis
- HRCT scan
- Genetic testing
- ANA
- Differential diagnosis
- Clinical presentation
- Patient case(s)
Treatment of SSc-ILD:
- Treatment overview and goals of therapy
- Current practice guidelines and standard care options
- Pharmacotherapy
- Immunosupressants
- Nintedanib
- Pirfenidone
- Antifibrinolytics
- Lung transplantation
- Patient education
- Patient case(s)
Learning Objectives
By the end of the session the participant will be able to:
- Describe the etiology of SSc-ILD and its impact on patient clinical presentation and available pharmacotherapeutic treatments
- Describe the prevalence, clinical features, and presentation of SSc-ILD
- Evaluate treatments plans for SSc-ILD patients and suggest appropriate therapies, where applicable, based on individual presentations
- Describe present and emerging drug therapies for management of SSc-ILD and apply them to patient cases taking into account the patient�s history
- Describe clinical and logistical challenges associated with treating and educating patients with SSc-ILD
Accreditation
ACCME Activity #201226485
THIS COURSE IS EXPIRED. NO CREDIT WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosures:
Dr. Terese C. Hammond, MD, Clinical Professor, University of Southern California, Los Angeles, CA has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care